Sinopharm CNBG COVID-19 vaccine
Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm.

They claim to be the world's first "second generation broadly protective" recombination protein subunit vaccine, i.e. by combining three heterogeneous antigens into one single trimer RBD protein (突变集成三聚化RBD, mutI-tri-RBD). It's based on the original, and the Beta (K417N/E484K/N501Y) and Kappa (L452R/E484K) variants.

References 

Clinical trials related to COVID-19
Chinese COVID-19 vaccines
Protein subunit vaccines